Authors: Bergh, J Wiklund, T Erikstein, B Lidbrink, E Lindman, H Malmstrom, P Kellokumpu-Lehtinen, P Bengtsson, NO Soderlund, G Anker, G Wist, E Ottosson, S Salminen, E Ljungman, P Holte, H Nilsson, J Blomqvist, C Wilking, N

Citation: J. Bergh et al., Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial, LANCET, 356(9239), 2000, pp. 1384-1391

Authors: Hjortsberg, C Persson, U Lidbrink, E Bennett, C

Citation: C. Hjortsberg et al., Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma, ACTA ONCOL, 38(8), 1999, pp. 1063-1067

Authors: Samuelsson, J Zackrisson, H Tokics, L Ljungman, P Lidbrink, E Pircher, P Larsson, L

Citation: J. Samuelsson et al., Acute quadriplegic myopathy following autologous peripheral blood stem cell transplantation for breast cancer, BONE MAR TR, 23(8), 1999, pp. 835-837